Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients

Published:2019-02-27 Issue:7 Volume:24 Page:807-814
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Watanuki Rurina,Hayashida Tetsu,Kawai Yuko,Kikuchi Masayuki,Nakashoji Ayako,Yokoe Takamichi,Toyota Tomoka,Seki Tomoko,Takahashi Maiko,Kitagawa Yuko

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/article/10.1007/s10147-019-01420-2/fulltext.html

Reference24 articles.

1. Seshadri R, Firgaira FA, Horsfall DJ et al (1993) Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11(10):1936–1942

2. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182

3. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712

4. Schramm A, De Gregorio N, Widschwendter P et al (2015) Targeted therapies in HER2-positive breast cancer—a systematic review. Breast Care (Basel) 10(3):173–178

5. Wuerstlein R, Harbeck N (2017) Neoadjuvant therapy for HER2-positive breast cancer. Rev Recent Clin Trials 12(2):81–92

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Value of Neoadjuvant Anthracycline-Based Regimens for HER2-Positive Breast Cancer: A Systematic Review and Meta-analysis Including 1366 Patients;Clinical Medicine Insights: Oncology;2023-01

2. Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer;Cancer Treatment and Research Communications;2023

3. Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?;Journal of Clinical Medicine;2022-12-06

4. Targeted therapeutic options and future perspectives for HER2-positive breast cancer;Signal Transduction and Targeted Therapy;2019-09-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3